C-X-C motif chemokine receptor 2 and C-X-C motif chemokine receptor 4 (CXCR2/CXCR4)

CXCR2 and CXCR4 are G protein-coupled receptors (GPCRs) that function as critical regulators of the chemokine signaling network, primarily governing the migration and positioning of immune and cancer cells [15, 18]. CXCR2 (C-X-C motif chemokine receptor 2) is predominantly expressed on neutrophils and endothelial cells, where it mediates acute inflammation and angiogenesis in response to ELR-positive chemokines such as CXCL8 (IL-8) [2, 4]. CXCR4 (C-X-C motif chemokine receptor 4) is widely expressed across hematopoietic and non-hematopoietic tissues, acting as the specific receptor for CXCL12 (SDF-1) to regulate hematopoiesis, lymphocyte homing, and embryonic development [5, 10]. The CXCR2/CXCR4 target designation refers to the functional axis or heterodimeric complex formed by these two receptors, which engage in significant crosstalk to drive disease progression, particularly in aggressive cancers such as pancreatic, gastric, and lung adenocarcinoma [1, 22, 25]. In the tumor microenvironment, this axis promotes tumor cell survival, metastasis, and the recruitment of immunosuppressive cells, making it a high-priority target for dual-inhibition strategies [8, 20]. Therapeutic interventions include small molecule antagonists and monoclonal antibodies that aim to disrupt ligand binding or receptor dimerization, thereby sensitizing tumors to conventional therapies and preventing metastatic spread [12, 13].

Other names

CD182 (CXCR2)CD184 (CXCR4)Interleukin 8 receptor beta (IL8RB)C-X-C chemokine receptor type 4FusinLESTRNPY3R

Competitive antagonism of CXCL8 and CXCL12 binding to their respective receptors, inhibition of G-protein mediated signaling (Gai), and disruption of receptor heterodimerization and functional crosstalk [8, 20, 25].